

Food and Drug Administration Rockville, MD 20857

TRANSMITTED BY FACSIMILE

Susan P. Rinne Vice President, Regulatory Affairs Alza Corporation 1900 Charleston Road P.O. Box 7210 Mountain View, CA 94039-7210

RE: NDA # 20-897

Ditropan XL® (oxybutynin chloride) Extended-Release Tablets MACMIS ID # 10196

Dear Ms. Rinne:

This letter objects to Alza Corporation's (Alza) dissemination of violative promotional materials for Ditropan XL (oxybutynin chloride) extended-release tablets. As part of its monitoring program, the Division of Drug Marketing, Advertising and Communications (DDMAC) has become aware of direct-to-consumer (DTC) broadcast and print advertisements for Ditropan XL that are false or misleading, in violation of the Federal Food, Drug, and Cosmetic Act (Act) and its implementing regulations. The DTC broadcast ("Stop and Go") and print (0011708) advertisements, submitted on Form FDA 2253, are violative for the reasons described below.

Inadequate Communication of Indication

The approved product labeling (PI) states that "Ditropan XL is a once-daily controlled-release tablet indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency." Your broadcast advertisement is misleading because it fails to adequately convey the symptoms of overactive bladder. Specifically, the supers describing these symptoms are displayed too briefly to be comprehended by consumers.

Overstatement of Efficacy

Broadcast Advertisement

Promotional materials are misleading if they suggest that a drug is more effective than has been demonstrated by substantial evidence. Your broadcast advertisement presents efficacy claims for Ditropan XL stating in the audio that "Ditropan XL is a prescription medication for overactive bladder proven to reduce wetting accidents by up to 90% versus 51% for a sugar pill" along with the prominent graphic of "90%" in the middle of the screen and the tagline "Reduces accidents by up to 90%." This overall presentation is unbalanced and, therefore, misleading because it overwhelmingly emphasizes the 90% reduction in wetting accidents with Ditropan XL. Furthermore, the graphic presenting that

Susan P. Rinne Alza Corporation NDA 20-897

Ditropan XL decreased wetting accidents from 16 to 2 per week while the sugar pill decreased wetting accidents from 21 to 11 per week is too complex for consumers to comprehend and assimilate in a 60-second broadcast advertisement.

In addition, your broadcast advertisement fails to prominently disclose important facts regarding the limitations of the clinical trials. Specifically, the clinical trials for Ditropan XL were set up to include only patients who were known to have had improved symptoms on oxybutynin, the active ingredient in Ditropan XL, or other similar medications used to treat overactive bladder. This qualifying message is not presented with adequate prominence to provide sufficient context to the efficacy claims. Your small super at the bottom of the screen briefly stating "Studies included patients known to be responsive to oxybutynin" fails to correct this misleading impression regarding the efficacy of Ditropan XL.

Print Advertisement

Similarly, your print advertisement claims that Ditropan XL "Reduces wetting accidents caused by overactive bladder by 83% to 90%" and "Once-a-day Ditropan XL reduced wetting accidents caused by overactive bladder by 83%-90%." Your print advertisement either fails to acknowledge or fails to prominently disclose that patients randomized to placebo experienced a 51% reduction in the number of wetting accidents. Similarly, your print advertisement fails to prominently disclose that the clinical trials were set up to include only patients who the sponsor knew would have improved symptoms on Ditropan XL because they were known to have had improved symptoms on oxybutynin, the active ingredient in Ditropan XL, or other similar medications used to treat overactive bladder. Again, this qualifying message is not presented with reasonably comparable prominence to the efficacy claims. Your graphic in the middle column in the print advertisement fails to correct this misleading impression regarding the efficacy of Ditropan XL.

Major Statement

The clutter and distraction of the moving car in the background during the presentation of the major statement in the broadcast advertisement minimizes the risks of Ditropan XL.

Requested Action

Alza should immediately discontinue these and all other promotional materials and activities for Ditropan XL that contain the same or similar claims or presentations. We request that Alza respond, in writing, with its intent to comply with the above. DDMAC should receive your written response no later than July 26, 2001. This response should list similarly violative materials with a description of the method for discontinuation and the discontinuation date.

If you have any questions or comments, please contact me by facsimile at (301) 594-6771, or at the Food and Drug Administration, Division of Drug Marketing, Advertising and Communications, HFD-42, Rm. 17B-20, 5600 Fishers Lane, Rockville, MD 20857. We remind you that only written communications are considered official.

In all future correspondence regarding this particular matter, please refer to MACMIS ID #10196 in addition to the NDA number.


Sincerely,

{See appended electronic signature page}


Barbara S. Chong, Pharm.D., BCPS Regulatory Review Officer Division of Drug Marketing, Advertising and Communications This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Barbara Chong 7/12/01 09:18:14 AM



ALZA
DITROPAN XL® (1 OF 3)
AZDT0176 :60 TV
05/03/01
"Stop and Go"



OPEN ON A MAP AS A SMALL TOY CAR DRIVES ACROSS A WINDING ROAD. SOUND EFFECTS OF A CAR STOPPING AND STARTING, DOORS OPENING AND CLOSING, FOOTSTEPS RUNNING BACK AND FORTH TO CAR. AS THEY SPEAK, A WOMAN....

Adele: Frank, stop here. Frank: What for? Adele: I gotta go.



AND MAN POP UP IN MULTIPLE IMAGES WITH THE MAP/CAR VISUAL.


Adele: Frank, pull in there. Frank: Can't you wait?

Adele: You want me to have an accident?



THE LOGO APPEARS. SYMPTOMS SUPER POPS UP.

AVO: Ditropan XL $^{\scriptsize\textcircled{\tiny{\$}}}$ is a prescription medication for overactive bladder proven



SUPERS POP UP.

to reduce wetting accidents by up to 90% versus 51% with a sugar pill. Isn't it time to ask your doctor about once-a-day Ditropan XL^{\oplus} ?



ALZA DITROPAN XL® (2 OF 3) AZDT0176 :60 TV 05/03/01 "Stop and Go"




CUT TO MAP, CAR, FRANK, AND ADELE.

Adele: Frank, if you don't pull over, we're gonna float to Phoenix!



LOGO AND PHONE NUMBER SUPER POP UP.

AVO: Ask your doctor about overactive bladder and if once-a-day Ditropan XL® is right for you... or call 1-888-395-1232 for more information.



CAR DRIVES ACROSS MAP WITH STOP-AND-START SOUND EFFECTS CONTINUING.

If you have certain types of stomach, urinary, or glaucoma problems, you should not take Ditropan XL®.

SUPER: Next TRIP.



CUT TO A DRIVE THROUGH TOWN.

Adele: Frank, stop there. Frank: You gotta go?



Cignal PHC

Temp


CC

GILA RIVER 10

ALZA DITROPAN XL® (3 OF 3) AZDT0176 :60 TV 4/16/01 "Stop and Go"

CAR KEEPS MOVING ALONG AS CUT TO FRANK AND ADELE.

Adele: No, my doctor prescribed Ditropan XL®. I'm fine. But, they've got the best chili in the world! Frank: (GROANS)



CAR DRIVES ACKOSS MAP WITH STOP-AND-START SOUND EFFECTS CONTINUING.

AVO: In studies, the most common side effect was dry mouth. Other side effects may include constipation, drowsiness, blurred vision, dizziness, diarrhea, and nausea.



ADELE RETURNS AS WEBSITE SUPER POPS UP AND THE LOGO FADES UP OVER MAP.

AVO: Why just live around your overactive bladder when it can be treated with Ditropan XL®?

ing



Reduces wetting accidents caused by overactive bladder by 83% to 90%.*




and Go.'

overactive I hours. *This and other clinical studies included patients known to have had symptoms improve with oxybutynin or other similar medications.



Oxybutynin chloride) Extended-rolease tablets 5, 10, 15 mg





Once-a-day <u>Ditropan XL®</u> reduced wetting accidents caused by overactive bladder by 83% to 90%.

51%

If you frequently have to find a bathroom in a hurry to prevent having wetting accidents, ask your doctor if Ditropan XL* is right for you.


Effective treatment for overactive bladder.

Overactive bladder is a common condition affecting more than 17,000,000 Americans. The symptoms include urge incontinence episodes (wetting accidents), urgency (a strong need to urinate), and frequency (urinating often).

It's important to know that overactive bladder is not a normal part of aging and you do not have to accept it as a way of life. Today, overactive bladder may be effectively treated for up to 24 hours with a single dose of Ditropan XL.

Proven to reduce wetting accidents by up to 90%.

In other words, in a clinical study, people who were experiencing 16 wetting accidents a week before Ditropan XL* were experiencing only 2 with Ditropan XL*. versus patients taking a sugar pill, where wetting accidents were not such as the production accidents were not such as the such as the



'This and other clinical studies included patients known to have symptoms improve with oxybutynin or other similar medications.

Otropan® and Ditropan XL® are registered trademarks of ALZA Corporation

Ask your doctor about Ditropan XL*.

The most common side effect with Ditropan XL* was dry mouth (61%). However, only 1% of people discontinued medication for this reason. Other common side effects may include constipation (13%), drowsiness (12%), diarrhea (9%), blurred vision (8%), dry eyes (6%), dizziness (6%), and runny nose (6%). Only 7% of patients in clinical studies discontinued therapy due to side effects. Do not take Ditropan XL* if you have certain types of stomach, urinary, or glaucorna problems.

Only your doctor can diagnose your bladder control problem. For more information about Ditropan XL*, speak to your doctor or call toll-free, 1-888-887-8620, or visit our web site at www.DitropanXL.com

Find out how the proven effectiveness of Ditropan XL* may be able to help you put a stop to "Stop and Go."

Please see brief summary of product information on next page



Helps stop "Stop and Go."

© 2001 ALZA Corporation

Once-a-day caused by o

Do you have

- Do you have t in a 24-hour p
- Do you often to urinate?
- Do you have a the bathroom?

If you are experiencin your bladder control t

*This and other clinical st or other similar medicati

Patient Jotornation Abo

DITROPAN 2 (oxybutynin chloride) \$\frac{1}{2}\$

Important Information for Patients Using DITROF
Please read this information before you start taking DITROF
refiled in case new information becomes available, th
books a rest unions. Ask your doctor or pharmacist to
the second proposals in the control or pharmacist to
the second proposals in the control or pharmacist to
the second proposals in the control or pharmacist to
the second proposals in the control or pharmacist to
the second proposals in the control or pharmacist to
the second proposals in the control or pharmacist to
the control or pharmacist to the

orman is not resourced. At a Company of overactive bigborsts, agreesly leveding to utriate introducibly), and in What should it library about overactive bindler? Ownarize bladder as a condition in which the muscless such situations, you may not be able to wait and m The symptoms of overactive bladder generally include u thrus deep other DPOPAN XE.

Doybulynen (the active medication in DITROPAN XL*) ac

Deep DTROPAN XLT cure overactive bindder? OTROPAN XLT is not a cure for overactive binder. It are encontracted (withing accessing, upgene) (mediday) if you are shift having binder cursholl problems all of: Your does of DTROPAN XLT are medid to be adjust When showed NOT table DTROPAN XLT?

DO NOT BEELD HIMMAN COLT.

You are abliged to opholyten or any of the ingredit

You have coltain types of placoma, unway, or do

Whall are the personnie size effects of DITROP,

In clinical studies, life modi commonly reported allow

politics, inseprises, neazeure, software, passes butter

Long youz, and unlawy lived intection. Seven porce

folicy and 1% anytoped because of by modify. The feet

Office lies reported side effects includes obmard-pain


gib band persons, regio free backs, libering, gar, and

resistatory that infection, cought, upper neads Conget
resistatory and of practical and the relief.

This is not a complete list of possible side effects. If you allocts, talk to your doctor or pharmacist.

How should I have DITEODEM VI+7.

Take UITHOPAN XL* tablets by mouth once a day,



! lime to

iould be PAN XI.